Loxo Oncology (LOXO) chief executive Dr. Joshua Bilenker negotiated the $8 billion sale of his company to Eli Lilly (LLY) in little more than two weeks, and did not approach any other suitors or engage in a bidding war.

According to a new filing with the Securities and Exchange Commission, Loxo believed that its most valuable asset was not its approved medicine, Vitrakvi, but an experimental one, the RET inhibitor LOXO-292.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Thanks for making your insonin so i can live.however it is so expensive it is a hardship. Their have been times i did not have money and had to be in hospital wondering if i would live. Now still stressed every month if i will be able to buy my insulin. it sucks to be at the mercy of big pharma.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy